Thyrocare Technologies Ltd

- There is no mention of any current or planned new fundraising through debt or equity in the provided text. - The company currently holds cash of INR 80 crores (both Thyrocare and ESL combined) primarily in debt mutual funds. - The management has been cautious about bidding for new government contracts to manage billing risk, indicating a conservative financial approach. - The focus appears to be on organic growth, partnership expansions, and capex investments (~INR 45 crores planned for FY '24), without reliance on new external fundraisings. - No explicit discussion about equity dilution or new debt issuance was noted in the call excerpts.

- FY '23 capex was close to INR 40 crores. - FY '24 capex budgeted around INR 45 crores. - Q1 FY '24 capex spend: INR 1.8 crores. - Major FY '24 capex allocations: - INR 15-20 crores for maintenance capex. - INR 10 crores for overhauling IT infrastructure. - INR 10 crores for expanding physical infrastructure within India. - INR 10 crores for international expansion, including Africa operations. - Strategic investment in expanding franchise business deeper into Tier 2+ India. - Setting up of JV operations in international markets like Africa, with ongoing team hiring and lab setup. - Investments made in expanding lab network and quality improvements (e.g., pathologists at each lab). - Focus on cautious bidding for government contracts directly by Thyrocare, not via partners.

- Franchise business grew 16% YoY and is expected to sustain similar growth throughout FY '24. - Partnerships business aims to recover to about 35%-36% share; overall growth expected around 12%-14%. - Focus on deepening franchise presence in Tier 2+ India regions with a targeted test menu. - D2C (Direct-to-Consumer) channel growing organically via remarketing and upselling; marketing-led growth model not yet adopted due to high customer acquisition costs. - Government contract participation is cautious and focused on areas like TB and infectious diseases, bidding directly as principal. - International expansion planned, with operations in Africa expected to start by year-end, aiming to replicate India's low-cost model. - Price structure changes to slab-based discounts promote volume growth and higher realization per patient. - Expect margins to hold around 31% (+/-1%) with controlled operating costs.

- Franchise business showed strong 16% YoY revenue growth; expected to sustain this growth throughout FY '24. - Partnership business expected to stabilize at around INR35 crores monthly, with cautious bidding on government contracts. - Overall revenue growth guidance for FY '24 is around 12-14%, driven by franchise expansion and partnership stabilization. - EBITDA margins for FY '24 are expected to stay around 31% ±1%. - Margin expansion potential exists but returning to earlier peak margins (~40%) is unlikely due to increased investments in lab network and quality. - Focus on cost control, operating leverage, and investment in quality to support margin improvement. - New pricing model (pay-for-performance) to sustain revenue and margin growth. - Esop costs ongoing but non-cash and accounted for; no impact on cash flow or equity dilution.

- Thyrocare mentioned expecting to recoup the partnership business through bidding for new government contracts. - These government contracts are bid directly by Thyrocare (as principal), not by partners. - Billing risk for these government contracts lies with Thyrocare. - The company is being cautious, focusing on government contracts in areas of strength like TB and infectious diseases. - No explicit specific figures or quantitative details about the current or expected order book or pending orders were provided in the transcript on page 15.